Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI)US-PRAYNCT07587294

Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction

A study testing Ultrasound modulation of the left stellate ganglion in people with Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI), run by Renmin Hospital of Wuhan University at 7 sites in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

The goal of this multicenter, double-blind, randomized controlled trial is to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) stellate ganglion modulation for preventing ventricular arrhythmias after ST-segment elevation myocardial infarction (STEMI) in patients undergoing percutaneous… Read more about this study

Who is it for?: Ages 18 to 80 years
Conditions the study is for: Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI)
What is being tested?: Ultrasound modulation of the left stellate ganglion
Type of treatment: Medical device
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 100 participants
Where: 7 sitesChina
Study dates: 15 May 2026to 1 Apr 2027
Phase: Interventional
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 80 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Age between 18 and 80 years (including 18 and 80 years); gender is not restricted;
Agree to be randomly assigned to a treatment strategy and be able to undergo follow-up as required;
Patients with a clinical diagnosis of acute ST-segment elevation myocardial infarction;
Presented within 12 hours of symptom onset and underwent PCI;
Killip functional class I-III;
Agree to participate in this study and voluntarily sign the informed consent form.

Who cannot join

Patients with a history of myocardial infarction;
Patients with a history of cardiac pacemaker or implantable cardioverter-defibrillator (ICD) implantation;
Patients with severe bradycardia or high-degree atrioventricular block;
Patients with severe heart failure (left ventricular ejection fraction <30%);
Patients with cardiogenic shock (Killip Class IV);
Patients admitted with frequent ventricular fibrillation or cardiac arrest;

Show all 15Show fewer

Patients with a history of malignant hematological disorders or renal failure (estimated eGFR <30 ml/min);
Patients with skin lesions, infections, or benign or malignant tumors in the left neck;
Pregnant or breastfeeding women, or women planning to become pregnant during the study;
Patients with severe cognitive impairment, psychiatric disorders, epilepsy, etc.;
Patients with concurrent malignant tumors or diseases of vital organs;
Patients with active systemic infections;
Patients who have participated in other drug or medical device clinical trials within the past 3 months;
Patients who are unable or unwilling to provide informed consent;
Patients deemed unsuitable for participation in this clinical trial by the investigator.

Trial locations and contacts

7 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Songyun Wang, MD contact

+86 13871262107

wsy7982@126.com

City, postcode or hospital

Sites recruiting now only

7 sites in 1 country

China7 sites, 7 recruiting

Huangshi Central Hospital
Huangshi, Hubei, 430060
Daoqun Jin, MD, +86 13597680361, edongheart@163.com
Not yet recruiting
Jingzhou Central Hospital
Jingzhou, Hubei, 430060
Keping Yang, MD, +86 18107168679, 30461400@qq.com
Not yet recruiting
Shiyan Taihe Hospital
Shiyan, Hubei, 430060
Huaqiang Xie, MD, +86 15971876767, xiehqiang@126.com
Not yet recruiting
Renmin Hospital of Wuhan University
Wuhan, Hubei, 430060
Songyun Wang, MD, +86 13871262107, wsy7982@126.com
Recruiting
Wuhan Central Hospital
Wuhan, Hubei, 430060
Long Wang, MD, +86 15827552859, 319921605@qq.com
Not yet recruiting
Wuhan Third Hospital
Wuhan, Hubei, 430060
Dongsheng Li, MD, +86 13100680307, lidongsheng693@sina.com
Not yet recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, 430060
Xiaolin WU, MD, +86 15571179695, 93316363@qq.com
Not yet recruiting

Other trials in China

About this study

Official title: Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction: A Multicenter, Double-blind Randomised Controlled Trial

The main questions it aims to answer are:

Does LIFU reduce the frequency and duration of ventricular arrhythmias within 72 hours post-PCI compared to sham ultrasound?
Does LIFU improve electrophysiological stability, myocardial injury markers, cardiac function and heart rate variability, and reduce inflammatory markers and sympathetic neurotransmitters?
What is the safety profile of LIFU in this population?

100 eligible patients will be randomized 1:1 to receive either active LIFU (2.0W, 1MHz, 50% duty cycle, 30min per session: 1 intra-PCI session + 7 daily post-PCI sessions) plus standard care, or identical sham ultrasound plus standard care. A comprehensive double-blind design (subjects, operators, assessors, statisticians) will be implemented. The study will run from May 2026 to April 2027 at 7 centers in China, led by Renmin Hospital of Wuhan University.

Participants will:

Complete pre-PCI screening and baseline assessments (informed consent, demographic/medical history, physical examination, electrocardiogram, echocardiogram, blood sample collection) within 12 hours of symptom onset
Receive 1 assigned ultrasound intervention during PCI, followed by 1 daily intervention for 7 consecutive days postoperatively
Undergo 72h continuous ECG monitoring post-PCI, blood sampling at baseline and postoperative days 1, 3, 7, and echocardiography assessment at postoperative day 7
Have all adverse events and arrhythmias recorded throughout the study
May withdraw voluntarily at any time without affecting routine medical care

Conditions: Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI)
Being tested: Ultrasound modulation of the left stellate ganglion, Sham ultrasound modulation of the left stellate ganglion
Keywords: Ultrasound, Stellate ganglion, Neuromodulation, STEMI, Ventricular arrhythmia
Medical subject headings: ST Elevation Myocardial Infarction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Ultrasound modulation of the left stellate ganglionDevice
Also called Ultrasound stellate ganglion modulation, LIFU
Subjects in this arm will receive low-intensity focused ultrasound (LIFU) intervention targeting the left stellate ganglion. The ultrasound probe and skin are disinfected, ultrasound coupling gel is applied, the probe is placed on the skin surface corresponding to the anatomical location of the left stellate ganglion, fixed with a robotic arm, and the instrument is activated. Ultrasound parameters: power 2.0 W, frequency 1 MHz, 50% duty cycle, 30 minutes per session. One session is performed during PCI, followed by once daily for 7 consecutive days postoperatively. All subjects will receive standard cardiovascular care in accordance with 2025 ACC/AHA guidelines, including PCI and indicated medications.
Sham ultrasound modulation of the left stellate ganglionDevice
Also called Sham ultrasound neuromodulation, Sham LIFU
Subjects in this arm will receive sham ultrasound intervention targeting the left stellate ganglion. The ultrasound probe and skin are disinfected, ultrasound coupling gel is applied, the probe is placed on the skin surface corresponding to the anatomical location of the left stellate ganglion and fixed with a robotic arm. No ultrasound energy is delivered, while the instrument maintains an identical appearance and operational state to the active LIFU arm. Ultrasound parameters: power 2.0 W, frequency 1 MHz, 50% duty cycle, 30 minutes per session. One sham session is performed during PCI, followed by once daily for 7 consecutive days postoperatively. All subjects will receive standard cardiovascular care in accordance with 2025 ACC/AHA guidelines, including PCI and indicated medications.

Study groups in NCT07587294
Study group	Role	What they receive
Ultrasound stimulation group	Experimental	Subjects in this arm will receive low-intensity focused ultrasound (LIFU) intervention targeting the left stellate ganglion. The ultrasound probe and skin are disinfected, ultrasound coupling gel is applied, the probe is placed on the skin surface corresponding to the anatomical location of the left stellate ganglion, fixed with a robotic arm, and the instrument is activated. Ultrasound parameters: power 2.0 W, frequency 1 MHz, 50% duty cycle, 30 minutes per session. One session is performed during PCI, followed by once daily for 7 consecutive days postoperatively. All subjects will receive standard cardiovascular care in accordance with 2025 ACC/AHA guidelines, including PCI and indicated medications. Receives: Device: Ultrasound modulation of the left stellate ganglion
Sham group	Placebo comparator	Subjects in this arm will receive sham ultrasound intervention targeting the left stellate ganglion. The ultrasound probe and skin are disinfected, ultrasound coupling gel is applied, the probe is placed on the skin surface corresponding to the anatomical location of the left stellate ganglion and fixed with a robotic arm. No ultrasound energy is delivered, while the instrument maintains an identical appearance and operational state to the active LIFU arm. Ultrasound parameters: power 2.0 W, frequency 1 MHz, 50% duty cycle, 30 minutes per session. One sham session is performed during PCI, followed by once daily for 7 consecutive days postoperatively. All subjects will receive standard cardiovascular care in accordance with 2025 ACC/AHA guidelines, including PCI and indicated medications. Receives: Device: Sham ultrasound modulation of the left stellate ganglion

What is being measured

The primary outcome is the main question the study is designed to answer.

Number of ventricular arrhythmias
Measurement: Count of ventricular arrhythmia episodes. Measurement device: Wearable Holter monitors.
Measured: 72 hours after PCI
Duration of ventricular arrhythmias
Measurement: Duration of ventricular arrhythmia episodes. Measurement device: Wearable Holter monitors.
Measured: 72 hours after PCI
NT-proBNP
Serum N-terminal pro-brain natriuretic peptide concentration; Unit: pg/mL
Measured: Baseline and 1, 3, 7 days after PCI

Secondary outcomes (26)

IL-1β level
Serum IL-1β concentration; Unit: pg/mL
Measured: Baseline and 1, 3, 7 days after PCI
Norepinephrine level
Serum norepinephrine concentration; Unit: pg/mL
Measured: Baseline and 1, 3, 7 days after PCI
Cardiac troponin T (cTnT) level
Serum cardiac troponin T concentration; Unit: ng/L
Measured: Baseline and 1, 3, 7 days after PCI
SDNN
Standard deviation of normal-to-normal intervals; Unit: ms Measurement device: Wearable Holter monitors
Measured: 72 hours after PCI
Left ventricular ejection fraction (LVEF)
Echocardiographic measurement of left ventricular systolic function; Unit: % Measurement device: Echocardiographic.
Measured: 7 days after PCI
Alanine aminotransferase (ALT) level
Serum alanine aminotransferase activity; Unit: U/L
Measured: Baseline and 7 days after PCI
Local skin temperature before and after stimulation
Measured: Baseline (before stimulation) and 30 minutes after stimulation
Serum creatinine level
Serum creatinine concentration; Unit: μmol/L
Measured: Baseline and 7 days after PCI
IL-6 level
Serum IL-6 concentration; Unit: pg/mL
Measured: Baseline and 1, 3, 7 days after PCI
TNF-α level
Serum TNF-α concentration; Unit: pg/mL
Measured: Baseline and 1, 3, 7 days after PCI
Neuropeptide Y level
Serum neuropeptide Y concentration; Unit: pg/mL
Measured: Baseline and 1, 3, 7 days after PCI
SDANN
Standard deviation of the averages of normal-to-normal intervals in all 5-minute segments; Unit: ms Measurement device: Wearable Holter monitors
Measured: 72 hours after PCI
Creatine kinase-MB (CK-MB) level
Serum creatine kinase-MB activity; Unit: U/L
Measured: Baseline and 1, 3, 7 days after PCI
SDANN
Standard deviation of the averages of NN intervals in all 5-minute segments; Unit: ms Measurement device: Wearable Holter monitors.
Measured: 72 hours after PCI
SDNN Index
Mean of the standard deviations of all NN intervals for all 5-minute segments ;Unit: ms Measurement device: Wearable Holter monitors.
Measured: 72 hours after PCI
RMSSD
Root mean square of successive differences between normal heartbeats
; Unit: ms Measurement device: Wearable Holter monitors.
Measured: 72 hours after PCI
pNN50
Percentage of successive NN intervals that differ by more than 50 ms
; Unit: % Measurement device: Wearable Holter monitors.
Measured: 72 hours after PCI
LF power
Low frequency power of heart rate variability; Unit: ms² Measurement device: Wearable Holter monitors.
Measured: 72 hours after PCI
HF power
High frequency power of heart rate variability; Unit: ms² Measurement device: Wearable Holter monitors.
Measured: 72 hours after PCI
LF/HF ratio
Ratio of low frequency to high frequency power; Unit: ratio Measurement device: Wearable Holter monitors.
Measured: 72 hours after PCI
Left ventricular end-systolic volume (LVESV)
Echocardiographic measurement of left ventricular volume at end-systole; Unit: mL Measurement device: Echocardiographic.
Measured: 7 days after PCI
Left ventricular end-systolic diameter (LVESD)
Echocardiographic measurement of left ventricular diameter at end-systole; Unit: mm Measurement device: Echocardiographic.
Measured: 7 days after PCI
Aspartate aminotransferase (AST) level
Serum aspartate aminotransferase activity; Unit: U/L
Measured: Baseline and 7 days after PCI
Blood urea nitrogen (BUN) level
Blood urea nitrogen concentration; Unit: mmol/L
Measured: Baseline and 7 days after PCI
Estimated glomerular filtration rate (eGFR)
Estimated glomerular filtration rate calculated using serum creatinine; Unit: mL/min
Measured: Baseline and 7 days after PCI
TP
Total power of heart rate variability; Unit: ms² Measurement device: Wearable Holter monitors.
Measured: 72 hours after PCI

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

15 May 20261 Apr 2027

First posted14 May 2026
Study start15 May 2026
Primary completion1 Apr 2027 (estimated)
Study completion1 Apr 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI)Studies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 100 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07587294
Sponsor's protocol ID: WDRY2026-K086
Other IDs: 82570593
Acronym: US-PRAY
Status last verified: Apr 2026
First submitted: 28 Apr 2026
Last updated: 21 Aug 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided: IPD sharing is currently undecided due to ongoing evaluation of participant privacy safeguards, data security requirements, and multicenter regulatory frameworks.

Study at a glance

From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction: A Multicenter, Double-blind Randomised Controlled Trial
ClinicalTrials.gov ID: NCT07587294
Acronym / sponsor ID: US-PRAY / WDRY2026-K086
Conditions: Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI)
Keywords: Ultrasound, Stellate ganglion, Neuromodulation, STEMI, Ventricular arrhythmia
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 100 participants (estimated)
Lead sponsor: Renmin Hospital of Wuhan UniversityUniversity, hospital or other
Collaborators: Wuhan Third Hospital, Xiangyang Central Hospital, Wuhan Central Hospital, Taihe Hospital, Jingzhou Central Hospital, Huangshi Central Hospital
Study start: 15 May 2026 (actual)
Primary completion: 1 Apr 2027 (estimated)
Study completion: 1 Apr 2027 (estimated)
First posted: 14 May 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The main questions it aims to answer are:

Does LIFU reduce the frequency and duration of ventricular arrhythmias within 72 hours post-PCI compared to sham ultrasound?
Does LIFU improve electrophysiological stability, myocardial injury markers, cardiac function and heart rate variability, and reduce inflammatory markers and sympathetic neurotransmitters?
What is the safety profile of LIFU in this population?

Participants will:

Complete pre-PCI screening and baseline assessments (informed consent, demographic/medical history, physical examination, electrocardiogram, echocardiogram, blood sample collection) within 12 hours of symptom onset
Receive 1 assigned ultrasound intervention during PCI, followed by 1 daily intervention for 7 consecutive days postoperatively
Undergo 72h continuous ECG monitoring post-PCI, blood sampling at baseline and postoperative days 1, 3, 7, and echocardiography assessment at postoperative day 7
Have all adverse events and arrhythmias recorded throughout the study
May withdraw voluntarily at any time without affecting routine medical care

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2

Arm	Type	Receives
Ultrasound stimulation group	Experimental	Device: Ultrasound modulation of the left stellate ganglionSubjects in this arm will receive low-intensity focused ultrasound (LIFU) intervention targeting the left stellate ganglion. The ultrasound probe and skin are disinfected, ultrasound coupling gel is applied, the probe is placed on the skin surface corresponding to the anatomical location of the left stellate ganglion, fixed with a robotic arm, and the instrument is activated. Ultrasound parameters: power 2.0 W, frequency 1 MHz, 50% duty cycle, 30 minutes per session. One session is performed during PCI, followed by once daily for 7 consecutive days postoperatively. All subjects will receive standard cardiovascular care in accordance with 2025 ACC/AHA guidelines, including PCI and indicated medications.
Sham group	Placebo comparator	Device: Sham ultrasound modulation of the left stellate ganglionSubjects in this arm will receive sham ultrasound intervention targeting the left stellate ganglion. The ultrasound probe and skin are disinfected, ultrasound coupling gel is applied, the probe is placed on the skin surface corresponding to the anatomical location of the left stellate ganglion and fixed with a robotic arm. No ultrasound energy is delivered, while the instrument maintains an identical appearance and operational state to the active LIFU arm. Ultrasound parameters: power 2.0 W, frequency 1 MHz, 50% duty cycle, 30 minutes per session. One sham session is performed during PCI, followed by once daily for 7 consecutive days postoperatively. All subjects will receive standard cardiovascular care in accordance with 2025 ACC/AHA guidelines, including PCI and indicated medications.

Who may qualify

Ages: 18 to 80 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (6 listed)

Age between 18 and 80 years (including 18 and 80 years); gender is not restricted;
Agree to be randomly assigned to a treatment strategy and be able to undergo follow-up as required;
Patients with a clinical diagnosis of acute ST-segment elevation myocardial infarction;
Presented within 12 hours of symptom onset and underwent PCI;
Killip functional class I-III;

Key exclusion criteria (15 listed)

Patients with a history of myocardial infarction;
Patients with a history of cardiac pacemaker or implantable cardioverter-defibrillator (ICD) implantation;
Patients with severe bradycardia or high-degree atrioventricular block;
Patients with severe heart failure (left ventricular ejection fraction <30%);
Patients with cardiogenic shock (Killip Class IV);

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Ultrasound modulation of the left stellate ganglionAlso: Ultrasound stellate ganglion modulation, LIFUSubjects in this arm will receive low-intensity focused ultrasound (LIFU) intervention targeting the left stellate ganglion. The ultrasound probe and skin are disinfected, ultrasound coupling gel is applied, the probe is placed on the skin surface corresponding to the anatomical location of the left stellate ganglion, fixed with a robotic arm, and the instrument is activated. Ultrasound parameters: power 2.0 W, frequency 1 MHz, 50% duty cycle, 30 minutes per session. One session is performed during PCI, followed by once daily for 7 consecutive days postoperatively. All subjects will receive standard cardiovascular care in accordance with 2025 ACC/AHA guidelines, including PCI and indicated medications.	Device	Ultrasound stimulation group
Sham ultrasound modulation of the left stellate ganglionAlso: Sham ultrasound neuromodulation, Sham LIFUSubjects in this arm will receive sham ultrasound intervention targeting the left stellate ganglion. The ultrasound probe and skin are disinfected, ultrasound coupling gel is applied, the probe is placed on the skin surface corresponding to the anatomical location of the left stellate ganglion and fixed with a robotic arm. No ultrasound energy is delivered, while the instrument maintains an identical appearance and operational state to the active LIFU arm. Ultrasound parameters: power 2.0 W, frequency 1 MHz, 50% duty cycle, 30 minutes per session. One sham session is performed during PCI, followed by once daily for 7 consecutive days postoperatively. All subjects will receive standard cardiovascular care in accordance with 2025 ACC/AHA guidelines, including PCI and indicated medications.	Device	Sham group

Primary outcome

Number of ventricular arrhythmias
Time frame: 72 hours after PCI
Measurement: Count of ventricular arrhythmia episodes. Measurement device: Wearable Holter monitors.
Duration of ventricular arrhythmias
Time frame: 72 hours after PCI
Measurement: Duration of ventricular arrhythmia episodes. Measurement device: Wearable Holter monitors.
NT-proBNP
Time frame: Baseline and 1, 3, 7 days after PCI
Serum N-terminal pro-brain natriuretic peptide concentration; Unit: pg/mL

26 secondary outcomes

IL-1β level
Time frame: Baseline and 1, 3, 7 days after PCI
Norepinephrine level
Time frame: Baseline and 1, 3, 7 days after PCI
Cardiac troponin T (cTnT) level
Time frame: Baseline and 1, 3, 7 days after PCI
SDNN
Time frame: 72 hours after PCI
Left ventricular ejection fraction (LVEF)
Time frame: 7 days after PCI
Alanine aminotransferase (ALT) level
Time frame: Baseline and 7 days after PCI
Local skin temperature before and after stimulation
Time frame: Baseline (before stimulation) and 30 minutes after stimulation
Serum creatinine level
Time frame: Baseline and 7 days after PCI
IL-6 level
Time frame: Baseline and 1, 3, 7 days after PCI
TNF-α level
Time frame: Baseline and 1, 3, 7 days after PCI
Neuropeptide Y level
Time frame: Baseline and 1, 3, 7 days after PCI
SDANN
Time frame: 72 hours after PCI
Creatine kinase-MB (CK-MB) level
Time frame: Baseline and 1, 3, 7 days after PCI
SDANN
Time frame: 72 hours after PCI
SDNN Index
Time frame: 72 hours after PCI
RMSSD
Time frame: 72 hours after PCI
pNN50
Time frame: 72 hours after PCI
LF power
Time frame: 72 hours after PCI
HF power
Time frame: 72 hours after PCI
LF/HF ratio
Time frame: 72 hours after PCI
Left ventricular end-systolic volume (LVESV)
Time frame: 7 days after PCI
Left ventricular end-systolic diameter (LVESD)
Time frame: 7 days after PCI
Aspartate aminotransferase (AST) level
Time frame: Baseline and 7 days after PCI
Blood urea nitrogen (BUN) level
Time frame: Baseline and 7 days after PCI
Estimated glomerular filtration rate (eGFR)
Time frame: Baseline and 7 days after PCI
TP
Time frame: 72 hours after PCI

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
Individual participant dataSharing planned: Undecided. IPD sharing is currently undecided due to ongoing evaluation of participant privacy safeguards, data security requirements, and multicenter regulatory frameworks.

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Songyun Wang, MD contact

+86 13871262107

wsy7982@126.com

7 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Songyun Wang, MD (+86 13871262107, wsy7982@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of ventricular arrhythmias (time frame: 72 hours after PCI). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07587294.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.